Recruiting
Phase 1
Phase 2

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT01371630

Conditions

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

Burkitt-Like Lymphoma With 11q Aberration

High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

High Grade B-Cell Lymphoma, Not Otherwise Specified

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Blinatumomab

Cyclophosphamide

Cytarabine

Dexamethasone

Inotuzumab Ozogamicin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information